---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-009717"
form_type: "8-K"
ticker: "QCLS"
cik: "0001321834"
company_name: "Q/C TECHNOLOGIES, INC."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T00:57:20.419676+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# TNF Pharmaceuticals holds investor call on Isomyosamine R&D progress

## Summary
- Conference call conducted March 6, 2025 to discuss research and development of lead compound Isomyosamine.
- Transcript furnished as Exhibit 10.1; no specific clinical or financial data provided in the available text.
- Company noted it undertakes no obligation to update the materials.

## SEC filing metadata
- accession: 0001493152-25-009717
- form_type: 8-K
- ticker: QCLS
- cik: 0001321834
- company_name: Q/C TECHNOLOGIES, INC.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321834/000149315225009717/0001493152-25-009717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321834/000149315225009717/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-009717
- JSON: https://secwatch.observer/filing/0001493152-25-009717.json
- Plain text: https://secwatch.observer/filing/0001493152-25-009717.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.